Indegene Limited (NSE:INDGN)
508.15
-1.70 (-0.33%)
Nov 17, 2025, 3:29 PM IST
Indegene Revenue
Indegene had revenue of 8.04B INR in the quarter ending September 30, 2025, with 17.09% growth. This brings the company's revenue in the last twelve months to 30.41B, up 12.23% year-over-year. In the fiscal year ending March 31, 2025, Indegene had annual revenue of 28.39B with 9.64% growth.
Revenue (ttm)
30.41B
Revenue Growth
+12.23%
P/S Ratio
4.01
Revenue / Employee
7.31M
Employees
4,158
Market Cap
121.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 28.39B | 2.50B | 9.64% |
| Mar 31, 2024 | 25.90B | 2.84B | 12.29% |
| Mar 31, 2023 | 23.06B | 6.41B | 38.54% |
| Mar 31, 2022 | 16.65B | 6.84B | 69.76% |
| Mar 31, 2021 | 9.81B | 3.37B | 52.36% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Aurobindo Pharma | 325.14B |
| Cipla | 279.66B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Biocon | 155.12B |
| Alkem Laboratories | 138.90B |
| Mankind Pharma | 135.46B |